Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 458

1.

Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis.

Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF.

Radiology. 2014 Dec;273(3):746-58. doi: 10.1148/radiol.14140033. Epub 2014 Jul 15.

2.

Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver.

Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B.

AJR Am J Roentgenol. 2009 Oct;193(4):1044-52. doi: 10.2214/AJR.08.1461.

PMID:
19770328
3.

Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.

Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF.

Radiology. 2015 May;275(2):438-47. doi: 10.1148/radiol.14141180. Epub 2014 Dec 19.

4.

Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: Prediction and assessment of response to transarterial chemoembolization. Preliminary experience.

Mannelli L, Kim S, Hajdu CH, Babb JS, Taouli B.

Eur J Radiol. 2013 Apr;82(4):577-82. doi: 10.1016/j.ejrad.2012.11.026. Epub 2012 Dec 14.

PMID:
23246330
5.

The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.

Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, Geschwind JF.

J Vasc Interv Radiol. 2006 Mar;17(3):505-12.

PMID:
16567675
6.

Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data.

Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR.

Radiology. 2011 Sep;260(3):752-61. doi: 10.1148/radiol.11102330. Epub 2011 Jul 19.

PMID:
21771960
7.

Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging.

Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF.

Radiology. 2009 Feb;250(2):466-73. doi: 10.1148/radiol.2502072222.

PMID:
19188315
8.

Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.

Vandecaveye V, Michielsen K, De Keyzer F, Laleman W, Komuta M, Op de beeck K, Roskams T, Nevens F, Verslype C, Maleux G.

Radiology. 2014 Mar;270(3):747-57. doi: 10.1148/radiol.13130591. Epub 2013 Dec 12.

PMID:
24475816
9.

Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.

Kokabi N, Camacho JC, Xing M, Edalat F, Mittal PK, Kim HS.

J Magn Reson Imaging. 2015 Oct;42(4):981-9. doi: 10.1002/jmri.24845. Epub 2015 Feb 12.

PMID:
25683022
10.

Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.

Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J, Chao M, Wang Z, Frangakis C, Sohn JH, Maltenfort MG, Pawlik T, Geschwind JF.

Radiology. 2016 Jan;278(1):275-84. doi: 10.1148/radiol.2015142951. Epub 2015 Jul 1.

11.

Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization.

Riaz A, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, Gates V, Nayar R, Wang E, Miller FH, Sato KT, Omary RA, Abecassis M, Salem R.

Cardiovasc Intervent Radiol. 2010 Dec;33(6):1143-52. doi: 10.1007/s00270-009-9766-5. Epub 2009 Dec 5.

12.

Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.

Shim JH, Han S, Shin YM, Yu E, Park W, Kim KM, Lim YS, Lee HC.

J Vasc Interv Radiol. 2013 Mar;24(3):316-25. doi: 10.1016/j.jvir.2012.10.022. Epub 2013 Jan 9.

PMID:
23312990
13.

Evaluation of treatment response of chemoembolization in hepatocellular carcinoma with diffusion-weighted imaging on 3.0-T MR imaging.

Sahin H, Harman M, Cinar C, Bozkaya H, Parildar M, Elmas N.

J Vasc Interv Radiol. 2012 Feb;23(2):241-7. doi: 10.1016/j.jvir.2011.08.030. Epub 2011 Oct 22.

PMID:
22019180
14.

Using intravoxel incoherent motion (IVIM) MR imaging to predict lipiodol uptake in patients with hepatocellular carcinoma following transcatheter arterial chemoembolization: a preliminary result.

Park YS, Lee CH, Kim JH, Kim IS, Kiefer B, Seo TS, Kim KA, Park CM.

Magn Reson Imaging. 2014 Jul;32(6):638-46. doi: 10.1016/j.mri.2014.03.003. Epub 2014 Mar 15.

PMID:
24703575
15.

Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma.

Bonekamp D, Bonekamp S, Halappa VG, Geschwind JF, Eng J, Corona-Villalobos CP, Pawlik TM, Kamel IR.

Eur J Radiol. 2014 Mar;83(3):487-96. doi: 10.1016/j.ejrad.2013.11.016. Epub 2013 Dec 3.

16.

Intravoxel incoherent motion diffusion-weighted MR imaging of hepatocellular carcinoma: correlation with enhancement degree and histologic grade.

Woo S, Lee JM, Yoon JH, Joo I, Han JK, Choi BI.

Radiology. 2014 Mar;270(3):758-67. doi: 10.1148/radiol.13130444. Epub 2013 Oct 30.

PMID:
24475811
17.

Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator?

Goshima S, Kanematsu M, Kondo H, Yokoyama R, Tsuge Y, Shiratori Y, Onozuka M, Moriyama N.

J Magn Reson Imaging. 2008 Apr;27(4):834-9. doi: 10.1002/jmri.21316.

PMID:
18383261
18.

Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction.

Kim S, Mannelli L, Hajdu CH, Babb JS, Clark TW, Hecht EM, Taouli B.

J Magn Reson Imaging. 2010 Feb;31(2):348-55. doi: 10.1002/jmri.22038.

PMID:
20099348
20.

Plain and gadolinium-DTPA-enhanced MR imaging of hepatocellular carcinoma treated with transarterial chemoembolization.

Castrucci M, Sironi S, De Cobelli F, Salvioni M, Del Maschio A.

Abdom Imaging. 1996 Nov-Dec;21(6):488-94.

PMID:
8875869

Supplemental Content

Support Center